Boehringer Ingelheim registers Phase I trial of immunotherapy BI 3822971 in solid tumors
The company listed a first-in-human dose-escalation study testing BI 3822971 across several advanced cancers, recruiting at sites in five countries.
Boehringer Ingelheim registered one new early-stage oncology trial this week.
- "A First-in-human, Open-label, Phase I Trial to Determine the Safety and Tolerability of BI 3822971 in Patients With Unresectable Advanced or Metastatic Solid Cancers" (NCT07744152) is recruiting. BI 3822971 is being developed to help the immune system fight cancer.1 The study plans to enroll an estimated 137 participants and is open to patients with advanced or metastatic solid cancer, such as non-small cell lung cancer, head and neck squamous cell carcinoma, triple-negative breast cancer, esophageal squamous cell carcinoma, bladder cancer, vulvar cancer, and cervical cancer.1 Primary outcomes include occurrence of treatment-emergent adverse events and occurrence of dose limiting toxicities, each measured up to 36 months.1 Of the 10 listed sites across Belgium, China, Germany, the Netherlands and Spain, only three in Spain (Hospital del Mar Barcelona, Hospital Universitario 12 de Octubre Madrid, and Clínica Universidad de Navarra) are currently recruiting, with the rest "not yet recruiting."
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.